Searchable abstracts of presentations at key conferences in endocrinology

ea0093oc18 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Towards an understanding of the microenvironment of ACC: Impact of steroid hormones and driver pathways

Maier Tanja , Landwehr Laura-Sophie , Sbiera Silviu , Schauer Marc P. , Schwarzmuller Paul , Fassnacht Martin , Kroisz Matthias

Background: Immune checkpoint therapy response rate in adrenocortical carcinoma (ACC) is only ~15%. Glucocorticoid (GC) secretion is present in ~60% of tumours, associated with adverse outcome and has been associated with an immunologically cold tumoural microenvironment. On the other hand, activation of the Wnt/ß-Catenin pathway has been suggested to contribute to reduced immune infiltration.Aims: First, we aim to improve the understanding of cellu...

ea0094oc2.4 | Endocrine Cancer and Late Effects | SFEBES2023

Communication between peri-prostatic adipocytes and epithelial cells drives prostate cancer aggressivity in obese men

Grunberg Nil , Qian Jiani , Tam Joseph , Lorentzen Marc , Winkler Mathias , Ahmed Hashim , Bevan Charlotte , Fletcher Claire

Prostate Cancer (PC) affects 1-in-6 men in the UK, and obesity 1-in-3, with rates of both increasing. High-fat diet is linked with increased risk of PC death, and volume of peri-prostatic adipose tissue (PPAT) is associated with increased risk of lethal PC/reduced therapy response. Despite this, molecular mechanisms underpinning obesity-driven PC remain poorly-understood. This is important since weight-gain and central obesity are major side-effects of PC trea...

ea0098b24 | Basic Science | NANETS2023

PARP inhibitors potentiate chemotherapy of NET cells and tumors and PAPR1-knockdown suppresses growth of NET tumors in mice#

Montoni Alicia , Shah Rashmi G. , Decobert Marc , Rajawat Jyotika , Richard Veronique , Merlin Marine A. , Girish M. Shah and

Background: In mammalian cells, poly(ADP-ribose) polymerase-1 (PARP1) is among the earliest proteins to reach the site of DNA damage and play key roles in different cellular responses ranging from DNA repair to cell death. PARP-inhibitors are recommended in mono or combination therapy for a subset of breast and ovarian cancers with BRCAness type of DNA repair deficiency. In addition, current clinical trials are examining whether PARP-inhibitors can potentiate the efficacy of c...

ea0099oc9.3 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Loss of heterozygosity predicts treatment-refractory behavior in pituitary neuroendocrine tumors

Lin Andrew , Rudneva Vasilisa , Richards Allison , Zhang Yanming , Rosenblum Marc , Donoghue Mark , Tabar Viviane , Geer Eliza

Background: Pituitary neuroendocrine tumors (PitNETs) exhibiting treatment-refractory behavior are the rare subset that progress after radiation and are characterized by unrelenting growth and metastatic dissemination.Methods: To identify biomarkers of treatment-refractory behavior, two groups of patients with PitNETs were consented to matched tumor-normal whole exome and targeted next-generation DNA sequencing on a clinical protocol: a prospective group...

ea0099p301 | Endocrine-Related Cancer | ECE2024

Dual targeting Boolean logic gate CAR-T cells for selective tumor antigen encounter exert potent antitumor efficacy in advanced adrenocortical carcinoma

Schauer Marc Philipp , Stabile Andrea , Landwehr Laura-Sophie , Altieri Barbara , Fassnacht Martin , Weber Justus , Hudecek Michael

Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy that produces glucocorticoids in 60% of cases causing clinically relevant hypercortisolism. Since, we observed in another study, that shaping these immunosuppressive and life-threatining properties with corticosteroid inhibitors not only led to a glucocorticoid receptor-related downregulation of ROR1 but also to the upregulation of another promising membrane bound oncogenic antigen* (AG), we sought to...

ea0084ps1-05-42 | Miscellaneous | ETA2022

Not all automated FT4 immunoassays measure accurately in samples of pregnant women and hemodialysis patients

Jansen Heleen , van Herwaarden Antonius , Vervloet Marc , Painter Rebecca , Huijgen Henk , Hillebrand Jacquelien , Boelen Anita , Heijboer Annemieke

Objectives: Free thyroxine (fT4) measurements are performed to detect thyroid disorders and monitor treatment. FT4 is measured using automated immunoassays (IAs) which face established analytical challenges due to low serum concentrations in the picomolar range and the precarious equilibrium between free and bound T4 (to thyroid-binding globulin (TBG) and (pre-)albumin). Furthermore, IAs are known to be affected by the composition of the serum sample (matrix-effects), which ca...

ea0088015 | Abstracts | BES2022

Modest changes in sex hormones during early and middle adulthood affect bone mass and size in healthy men. A prospective cohort study

Thiberiu Banica , Charlotte Verroken , Guy T'Sjoen , Stefan Goemaere , Hans-Georg Zmierczak , Tom Fiers , Jean-Marc Kaufman , Bruno Lapauw

Bone metabolism in men is in part determined by sex steroid exposure. This is especially clear during puberty and senescence but it remains to be established whether declines in sex steroid levels during young and middle adulthood associate with changes in bone mass and size. This study investigated changes in bone mineral content (BMC), areal and volumetric bone density (aBMD; vBMD) and bone size in relation to sex steroid levels in 999 young adult men (age 24- 46 years) of w...

ea0090p398 | Endocrine-related Cancer | ECE2023

Severe insulin secretion by an inoperable metastatic insulinoma can be controlled by 177-Lu-DOTA-TATE radionuclide therapy: a case report

Riley George , Creton Cecile , Demarquet Lea , Raymond Perrine , Chevalier Elodie , Lambert Aurelien , Guerci Bruno , Klein Marc , Scheyer Nicolas

Introduction: Metastatic insulinoma is an extremely rare form of malignant insulinoma involving metastatic growth where classical surgical treatment is often impossible. Medical therapies are widely considered and reserved for those especially with inoperable insulinoma with the goals of reducing tumor size, but also of reducing hypoglycemic events either by acting directly on the insulinoma cells (reducing excess insulin secretion from the insulinoma cells or reducing tumor v...

ea0063gp44 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Effects of anti-inflammatory treatment on fibroblast growth factor-21 in obesity and metabolic syndrome

Ebrahimi Fahim , Urwyler Sandrine , Betz Matthias , Christ Emanuel , Schuetz Philipp , Mueller Beat , Donath Marc , Mirjam Christ-Crain

Background: Fibroblast growth factor-21 (FGF21), which has recently been identified as a central regulator of metabolism, is known to be increased in conditions of obesity, insulin resistance, and fatty liver. Likewise, there is evidence that FGF21 increases with systemic inflammation. The aim of this study was to evaluate whether chronic low-grade inflammation might be the underlying mechanism and whether an anti-inflammatory treatment decreases FGF21 levels in metabolic diso...

ea0063gp109 | Calcium and Bone 2 | ECE2019

Sex steroids as determinants of Wnt-Signalling markers in men

Banica Thiberiu , Verroken Charlotte , Zmierczak Hans-Georg , Goemaere Stefan , Defreyne Justine , T'Sjoen Guy , Kaufman Jean-Marc , Lapauw Bruno

Background: Canonical Wnt-signalling is important for bone by regulating osteoblastogenesis and osteoblast function. Bone metabolism is also partly determined by sex steroid exposure and sex differences in serum sclerostin levels have been reported. However, it is unclear whether serum sclerostin and other circulating Wnt-signalling components are sex steroid dependent within healthy men.Objective: To determine whether serum sclerostin, osteoprotegerin (...